# A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

> **NCT07064863** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Queen's University** · enrollment: 31 (estimated)

## Conditions studied

- NMIBC
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Bladder (Urothelial, Transitional Cell) Cancer
- Urothelial Carcinoma Bladder

## Interventions

- **DRUG:** Gemcitabine + BCG
- **DRUG:** BCG (TICE strain)

## Key facts

- **NCT ID:** NCT07064863
- **Lead sponsor:** Queen's University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064863, "A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07064863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*